Lv1
50 积分 2023-07-11 加入
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
3天前
已完结
Updates on the treatment of invasive breast cancer: Quo Vadimus?
15天前
已完结
An overview of the research progress of BRCA gene mutations in breast cancer
22天前
已完结
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
1个月前
已完结
PARP Inhibitors for Breast Cancer Treatment
1个月前
已完结
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
2个月前
已完结
St. Gallen 2007: Breast Cancer Treatment Consensus Report
2个月前
已完结
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
4个月前
已完结
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
5个月前
已完结
皖公网安备34019202002308
